Parallel Advisors, LLC Avadel Pharmaceuticals PLC Transaction History

Parallel Advisors, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 20, 2024	BUY	$6.41 - $9.95 $269 - $417	42 New	42 $0
Q1 2023 Apr 25, 2023	BUY	$6.41 - $9.95 $269 - $417	42 New	42 $0
Q2 2021 Aug 06, 2021	BUY	$6.73 - $9.05 $861 - $1,158	128 New	128 $1,000
Q2 2018 Jul 30, 2018	SELL	$5.89 - $7.78 $4,105 - $5,422	-697 Closed	0 $0
Q1 2018 May 08, 2018	SELL	$6.76 - $11.7 $1,784 - $3,088	-264 Reduced 27.47%	697 $5,000
Q4 2017 Feb 13, 2018	BUY	$8.03 - $11.25 $7,716 - $10,811	961	961 $8,000

1.07M

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.